Yi-Ping Chen

Yi-Ping Chen

Auto-generated profile, based on publicly available information

Yi-Ping Chen

Graduate Institute of Nanomedicine and Medical Engineering, Taipei Medical University, Taipei 11031, Taiwan

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2013 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
YCYi-Ping Chen
Yi-Ping Chen
CCChien-Tsu Chen
Chien-Tsu Chen
YHYann Hung
Yann Hung
CCChih-MIng Chou
Chih-MIng Chou
TLTsang-Pai Liu
Tsang-Pai Liu
CMChung-Yuan Mou
Chung-Yuan Mou

8 May 2024 in ACS Nano
Verified
Journal Article
Open access
ZCZih-An Chen
Zih-An Chen
CWCheng-Hsun Wu
Cheng-Hsun Wu
SWSi-Han Wu
Si-Han Wu
CHChiung-Yin Huang
Chiung-Yin Huang
CMChung-Yuan Mou
Chung-Yuan Mou
PCPeilin Chen
Peilin Chen
Mesoporous silica nanoparticles (MSNs) represent a promising avenue for targeted brain tumor therapy. However, the blood-brain barrier (BBB) often presents a formidable obstacle to efficient drug delivery. This study introduces a ligand-free PEGylated MSN variant (RMSN25-PEG-TA) with a 25 nm size and a slight positive charge, which exhibits superior BBB penetration. Utilizing two-photon imaging, RMSN25-PEG-TA particles remained in circulation for over 24 h, indicating significant traversal beyond the cerebrovascular realm. Importantly, DOX@RMSN25-PEG-TA, our MSN loaded with doxorubicin (DOX), harnessed the enhanced permeability and retention (EPR) effect to achieve a 6-fold increase in brain accumulation compared to free DOX. In vivo evaluations confirmed the potent inhibition of orthotopic glioma growth by DOX@RMSN25-PEG-TA, extending survival rates in spontaneous brain tumor models by over 28% and offering an improved biosafety profile. Advanced LC-MS/MS investigations unveiled a distinctive protein corona surrounding RMSN25-PEG-TA, suggesting proteins such as apolipoprotein E and albumin could play pivotal roles in enabling its BBB penetration. Our results underscore the potential of ligand-free MSNs in treating brain tumors, which supports the development of future drug-nanoparticle design paradigms.

11 December 2020 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
YCYi-Ping Chen
Yi-Ping Chen
LXLi Xu
Li Xu
TTTao-Wei Tang
Tao-Wei Tang
CCCheuh-Hsuan Chen
Cheuh-Hsuan Chen
QZQuan-Hong Zheng
Quan-Hong Zheng
SWSi-Han Wu
Si-Han Wu

15 April 2019 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
CCCheng-Shun Cheng
Cheng-Shun Cheng
TLTsang-Pai Liu
Tsang-Pai Liu
FCFan-Ching Chien
Fan-Ching Chien
CMChung-Yuan Mou
Chung-Yuan Mou
SWSi-Han Wu
Si-Han Wu
YCYi-Ping Chen
Yi-Ping Chen

17 April 2024 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
THTsung-I Hsu
Tsung-I Hsu
YCYi-Ping Chen
Yi-Ping Chen
RZRong-Lin Zhang
Rong-Lin Zhang
ZCZih-An Chen
Zih-An Chen
CWCheng-Hsun Wu
Cheng-Hsun Wu
SWSi-Han Wu
Si-Han Wu
While temozolomide (TMZ) has been a cornerstone in the treatment of newly diagnosed glioblastoma (GBM), a significant challenge has been the emergence of resistance to TMZ, which compromises its clinical benefits. Additionally, the nonspecificity of TMZ can lead to detrimental side effects. Although TMZ is capable of penetrating the blood-brain barrier (BBB), our research addresses the need for targeted therapy to circumvent resistance mechanisms and reduce off-target effects. This study introduces the use of PEGylated mesoporous silica nanoparticles (MSN) with octyl group modifications (C8-MSN) as a nanocarrier system for the delivery of docetaxel (DTX), providing a novel approach for treating TMZ-resistant GBM. Our findings reveal that C8-MSN is biocompatible in vitro, and DTX@C8-MSN shows no hemolytic activity at therapeutic concentrations, maintaining efficacy against GBM cells. Crucially, in vivo imaging demonstrates preferential accumulation of C8-MSN within the tumor region, suggesting enhanced permeability across the blood-brain tumor barrier (BBTB). When administered to orthotopic glioma mouse models, DTX@C8-MSN notably prolongs survival by over 50%, significantly reduces tumor volume, and decreases side effects compared to free DTX, indicating a targeted and effective approach to treatment. The apoptotic pathways activated by DTX@C8-MSN, evidenced by the increased levels of cleaved caspase-3 and PARP, point to a potent therapeutic mechanism. Collectively, the results advocate DTX@C8-MSN as a promising candidate for targeted therapy in TMZ-resistant GBM, optimizing drug delivery and bioavailability to overcome current therapeutic limitations.

9 January 2019 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
ZCZih-An Chen
Zih-An Chen
SWSi-Han Wu
Si-Han Wu
PCPeilin Chen
Peilin Chen
YCYi-Ping Chen
Yi-Ping Chen
CMChung-Yuan Mou
Chung-Yuan Mou